Efficacy and tolerability of lercanidipine in patients with hypertension: Results of a Phase IV study in general practice

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 14, 2007, Pages 2215-2223

  Burnier, Michel ^a   Gasser, Urs E ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ClinResearch GmbH   (Switzerland)

Author keywords

Blood pressure control; Calcium antagonists; Diabetes; Hypertension; Side effects

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LERCANIDIPINE;

ADD ON THERAPY; ADULT; AGED; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CLINICAL TRIAL; COLD SENSATION; COMBINATION CHEMOTHERAPY; COUGHING; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; GENERAL PRACTICE; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; PERIPHERAL EDEMA; PHASE 4 CLINICAL TRIAL; PHYSICIAN; POPULATION RESEARCH; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWITZERLAND;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; DIHYDROPYRIDINES; FAMILY PRACTICE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SLEEP DISORDERS;

EID: 35548936535     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.14.2215     Document Type: Article

References (18)

1. WOLF-MAIER K, COOPER RS, KRAMER H et al.: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension (2004) 43:10-17.
2. LEWINGTON S, CLARKE R, QIZILBASH N, PETO R, COLLINS R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 360:1903-1913.
3. BURNIER M: Medication adherence and persistence as the cornerstone of effective antihyperrensive therapy. Am. J. Hypertens. (2006) 19:1190-1196.
4. BURNIER M, HESS B, GREMINGER P, WAEBER B: Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey. BMC Cardiovasc. Disord. (2005) 5:13.
5. JULIUS S, KJELDSEN SE, WEBER M et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet (2004):1-10.
6. WRIGHT JT Jr, DUNN JK, CUTLER JA et al.; ALLHAT COLLABORATIVE RESEARCH GROUP: Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 293:1595-1160.
7. STAESSEN JA, FAGARD R, THIJS L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet (1997) 350:757-764.
8. POULTER NR, WEDEL H, DAHLOF B et al.; ASCOT INVESTIGATORS: Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA). Lancet (2005) 366:907-913.
9. VAN ZWIETEN PA, MANCIA G: Third generation calcium antagonists: further developments. Blood Press. (1996) 5:367-377.
10. MEREDITH PA: Lercanidipine: a novel lipophilic dihydropyridin calcium antagonist with long duration of action and high vascular selectivity. Expert Opin. Investig. Drugs (1999) 8:1043-1062.
11. DEGIORGIO LA, ORLANDINI F, MALASOMA P, ZAPPA A: Double-blind, cross-over study of lercanidipine versus amlodipine in the treatment of mild to moderate essential hypertension. Curr. Ther. Res. (1999)60:511-520.
12. BORGHI C, PRANDIN MG, DORMI A, AMBROSIONI E; STUDY GROUP OF THE REGIONAL UNIT OF THE ITALIAN SOCIETY OF HYPERTENSION: Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press. Suppl. (2003) 1:14-21.
13. TOPOUCHIAN JA, EL ASSAAD MA, OROBINSKAIA LV, EL FEGHALI RN, ASMAR RG: Validation of two devices for self-measurement of brachial blood pressure according to the international protocol of the European society of hypertension: the SEINEX SE 9400 and the Microlife BP 3AC1-1. Blood Press. Monit. (2005) 10:325-331.
14. BARRIOS V, NAVARRO A, ESTERAS A et al.: Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press. (2002) 11:95-100.
15. LEONETTI G, MAGNANI B, PESSINA AC, RAPPELLI A, TRIMARCO B, ZANCHETTI A; COHORT STUDY GROUP: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. (2002) 15:932-940.
16. CHERUBINI A, FABRIS F, FERRARI E et al.: Comparative effects of lercanidipine, lacidipine and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch. Gerontal. Geriatr. (2003) 37:203-212.
17. DALLA VESTRA M, POZZA G, MOSCA A et al.: Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study. Diabetes Nutr. Metab. (2004) 17:259-266.
18. 2003 EUROPEAN SOCIETY OF HYPERTENSION: European society of cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1011-1053.